Press Release: Novartis secures exclusive rights -2-

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach nearly 800 million people globally

and we are finding innovative ways to expand access to our latest

treatments. About 110,000 people of more than 140 nationalities work at

Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit

https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

1. Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and

outcomes in hospitalized patients with COVID-19: a global literature

survey. Crit Care. 2020;24(1):516.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441837/

2. Matthay MA, Zemans RL. The acute respiratory distress syndrome:

pathogenesis and treatment. Annu Rev Pathol. 2011;6:147-163.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108259/

3. MSCs in COVID-19 ARDS. ClinicalTrials.gov identifier: NCT04371393.

https://www.clinicaltrials.gov/ct2/show/NCT04371393

4. Mesoblast Ltd. 83% Survival in COVID-19 Patients with Moderate/Severe

Acute Respiratory Distress Syndrome Treated in New York with Mesoblast's

cell therapy Remestemcel-L.; 2020

https://investorsmedia.mesoblast.com/static-files/337e723a-340d-493e-a4a1-0971d2c71460

5. National Health Service - National Institute for Health Research.

Remestemcel-L (Prochymal) for steroid refractory acute graft versus host

disease -- second line.; 2015

http://www.io.nihr.ac.uk/wp-content/uploads/migrated/Remestemcel-L-July2015.pdf

6. Fitzsimmons REB et al. Mesenchymal Stromal/Stem Cells in Regenerative

Medicine and Tissue Engineering. Stem Cells Int. 2018;2018:8031718.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120267/

7. Gotts JE, Matthay MA. Mesenchymal stem cells and acute lung injury. Crit

Care Clin. 2011;27(3):719-733.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134785/

8. Horwitz EM, Andreef M, Frassoni F. Mesenchymal stromal cells. Curr Opin

Hematol. 2006;13(6):419-425.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365862/

9. Thompson M et al. Cell therapy with intravascular administration of

mesenchymal stromal cells continues to appear safe: An updated systematic

review and meta-analysis. EClinicalMedicine. 2020;19,

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(19)30258-

5/fulltext

10. Diamond M, Peniston Feliciano HL, Sanghavi D, et al. Acute Respiratory

Distress Syndrome. StatPearls Publishing.

https://www.ncbi.nlm.nih.gov/books/NBK436002/

11. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute

respiratory distress syndrome. J Intensive Care Med. 2006;21(3):119-143.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765330/

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Peter Zuest Phil McNamara

Novartis External Communications Global Head, Respiratory Communications

+41 79 899 98 12 (mobile) +41 79 510 87 56 (mobile)

peter.zuest@novartis.com philip mailto:philip.mcnamara@novartis.com

Novartis US External Communications.mcnamara@novartis.com

+1 646 438 43 35

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

November 19, 2020 16:30 ET (21:30 GMT)